Search
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Categories: Complement C5 inhibitorsProducts: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigationalGrowth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and
Synonyms: (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247, Recombinant human growth hormone long acting (fused w beta chains of HCG)Products: NGENLA 24 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, NGENLA 60 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADETEntecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalEntecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). … Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine
Categories: Hepatitis B virus, Cytochrome P-450 SubstratesProducts: KALVIR® 1 MG, ZENTAIR 1 MGDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.
Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-AminopyridineHemin
go.drugbank.com/drugs/DB03404ApprovedInvestigationalHemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More RingsProducts: Normosang 25 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, PANHEMATIN® POLVO ESTERIL LIOFILIZADO PARA INYECCIÓN 350 MG/ VIALOmalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalOmalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). … [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.
Products: XOLAIR ® 150 MG, XOLAİR 75 MG/0.5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETOrotic aciduria
go.drugbank.com/conditions/DBCOND0024003Drugs: Uridine triacetateSynonyms: Deficiency of orotidine-5'-phosphate pyrophosphorylaseRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigational[A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: DAXAS®, ROFLUNG 0,5 MG SAŞE ,30 SAŞESatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalSatralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on … occurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the
Categories: Interleukin-6 Receptor AntagonistSynonyms: Humanised anti-IL-6 receptor monoclonal antibodySecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Products: VERXANT 150 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, VERXANT 150 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET